Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

News Release

 View printer-friendly version

Charles River Laboratories Completes Sale of Clinical Phase II - IV Business

WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 16, 2006--Charles River Laboratories International, Inc. (NYSE: CRL) today completed the previously announced sale of its Phase II-IV Clinical Services business to Kendle International Inc. The sale of the business was completed in accordance with the terms and conditions of the Stock Purchase Agreement, as amended, between Charles River and Kendle dated as of May 9, 2006.

About Charles River Laboratories

Charles River Laboratories, based in Wilmington, Massachusetts, partners with global pharmaceutical and biotechnology companies to advance the drug discovery and development process, bringing drugs to market faster and more efficiently. Charles River's 7,500 employees serve clients worldwide. For more information on Charles River, visit our website at www.criver.com.

CONTACT: Charles River Laboratories International, Inc.
Investor Contact:
Susan E. Hardy, 781-262-7616
Corporate Vice President, Investor Relations
or
Media Contact:
Elizabeth Ferber, 978-658-6000 Ext.1693
Director, Corporate Communications

SOURCE: Charles River Laboratories International, Inc.

Featured Report

2018 Annual Report (PDF)

Investor Hotline

877-567-6CRL (6275)